Markers for the detection of Lewy body disease versus Alzheimer's disease in mild cognitive impairment: a systematic review and meta-analysis

CONCLUSIONS: Few studies have assessed the accuracy of biomarkers and clinical tools to distinguish DLB from AD at the MCI stage. While results are promising for CSF markers, FDG-PET and clinical symptoms scales, more studies, particularly with a prospective design, are needed to evaluate their accuracy and clinical usefulness.CLINICAL TRIAL REGISTRATION: Prospero (CRD42023422600).PMID:38451331 | PMC:PMC10920203 | DOI:10.1007/s40520-024-02704-y

Source: Aging Clinical and Experimental Research - March 7, 2024 Category: Geriatrics Authors: Marianna Ilarj Burgio Nicola Veronese Davide Sar à Carlo Saccaro Roberta Masnata Giusy Vassallo Angela Catania Giuseppina Catanese Christoph Mueller Lee Smith Ligia Juliana Dominguez Laura Vernuccio Mario Barbagallo Source Type: research